Literature DB >> 18035282

In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.

Ming Q Huang1, David S Nelson, Stephen Pickup, Hui Qiao, E James Delikatny, Harish Poptani, Jerry D Glickson.   

Abstract

RATIONALE AND
OBJECTIVES: A reliable noninvasive method for in vivo detection of early therapeutic response of non-Hodgkin's lymphoma (NHL) patients would be of great clinical value. This study evaluates the feasibility of (1)H and (31)P magnetic resonance spectroscopy (MRS) for in vivo detection of response to combination chemotherapy of human diffuse large B-cell lymphoma (DLCL2) xenografts in severe combined immunodeficient (SCID) mice.
MATERIALS AND METHODS: Combination chemotherapy with cyclophosphamide, hydroxy doxorubicin, Oncovin, prednisone, and bryostatin 1 (CHOPB) was administered to tumor-bearing SCID mice weekly for up to four cycles. Spectroscopic studies were performed before the initiation of treatment and after each cycle of the CHOPB. Proton MRS for detection of lactate and total choline was performed using a selective multiple-quantum-coherence-transfer (Sel-MQC) and a spin-echo-enhanced Sel-MQC (SEE-Sel-MQC) pulse sequence, respectively. Phosphorus-31 MRS using a nonlocalized, single-pulse sequence without proton decoupling was also performed on these animals.
RESULTS: Significant decreases in lactate and total choline were detected in the DLCL2 tumors after one cycle of CHOPB chemotherapy. The ratio of phosphomonoesters to beta-nucleoside triphosphate (PME/betaNTP, measured by (31)P MRS) significantly decreased in the CHOPB-treated tumors after two cycles of CHOPB. The control tumors did not exhibit any significant changes in either of these metabolites.
CONCLUSIONS: This study demonstrates that (1)H and (31)P MRS can detect in vivo therapeutic response of NHL tumors and that lactate and choline offer a number of advantages over PMEs as markers of early therapeutic response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035282      PMCID: PMC2148497          DOI: 10.1016/j.acra.2007.07.012

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  47 in total

1.  Two-compartment model for determination of glycolytic rates of solid tumors by in vivo 13C NMR spectroscopy.

Authors:  D Artemov; Z M Bhujwalla; U Pilatus; J D Glickson
Journal:  NMR Biomed       Date:  1998-11       Impact factor: 4.044

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors.

Authors:  J Star-Lack; D Spielman; E Adalsteinsson; J Kurhanewicz; D J Terris; D B Vigneron
Journal:  J Magn Reson       Date:  1998-08       Impact factor: 2.229

4.  Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

Authors:  A M Al-Katib; M R Smith; W S Kamanda; G R Pettit; M Hamdan; A N Mohamed; B Chelladurai; R M Mohammad
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

5.  Lymphoma: diagnosis, staging, natural history, and treatment strategies.

Authors:  Pier Luigi Zinzani
Journal:  Semin Oncol       Date:  2005-02       Impact factor: 4.929

Review 6.  Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.

Authors:  Ali R Jazirehi; Benjamin Bonavida
Journal:  Oncogene       Date:  2005-03-24       Impact factor: 9.867

7.  Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors.

Authors:  E O Aboagye; Z M Bhujwalla; D C Shungu; J D Glickson
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

8.  Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.

Authors:  Lesley D McPhail; Yuen-Li Chung; Basetti Madhu; Simon Clark; John R Griffiths; Lloyd R Kelland; Simon P Robinson
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

9.  In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma.

Authors:  Roger M Bourne; Peter Stanwell; Jonathan R Stretch; Richard A Scolyer; John F Thompson; Carolyn E Mountford; Cynthia L Lean
Journal:  Eur J Radiol       Date:  2005-03       Impact factor: 3.528

10.  Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T.

Authors:  Peter Stanwell; Laurence Gluch; David Clark; Boguslaw Tomanek; Luke Baker; Bruno Giuffrè; Cynthia Lean; Peter Malycha; Carolyn Mountford
Journal:  Eur Radiol       Date:  2004-09-03       Impact factor: 5.315

View more
  11 in total

1.  Prediction and Early Detection of Response by NMR Spectroscopy and Imaging.

Authors:  Seung-Cheol Lee; Fernando Arias-Mendoza; Harish Poptani; E James Delikatny; Mariusz Wasik; Michal Marzec; Stephen J Schuster; Sunita D Nasta; Jakub Svoboda; Owen A O'Connor; Mitchell R Smith; Jerry D Glickson
Journal:  PET Clin       Date:  2012-01

2.  A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts.

Authors:  Ting Liu; Kavindra Nath; Weixia Liu; Rong Zhou; I-Wei Chen
Journal:  NMR Biomed       Date:  2015-07-14       Impact factor: 4.044

Review 3.  Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.

Authors:  Kanchan Sonkar; Vinay Ayyappan; Caitlin M Tressler; Oluwatobi Adelaja; Ruoqing Cai; Menglin Cheng; Kristine Glunde
Journal:  NMR Biomed       Date:  2019-06-11       Impact factor: 4.044

4.  Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models.

Authors:  S Magnitsky; G K Belka; C Sterner; S Pickup; L A Chodosh; J D Glickson
Journal:  NMR Biomed       Date:  2012-07-05       Impact factor: 4.044

5.  Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin.

Authors:  Yu-Jie Jiang; Qing Sun; Xiao-Sheng Fang; Xin Wang
Journal:  Mol Med       Date:  2009-02-05       Impact factor: 6.354

6.  Evaluation of diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) as early response biomarkers in cervical cancer patients.

Authors:  Stefania Rizzo; Valentina Buscarino; Daniela Origgi; Paul Summers; Sara Raimondi; Roberta Lazzari; Fabio Landoni; Massimo Bellomi
Journal:  Radiol Med       Date:  2016-07-02       Impact factor: 3.469

Review 7.  High-field small animal magnetic resonance oncology studies.

Authors:  Louisa Bokacheva; Ellen Ackerstaff; H Carl LeKaye; Kristen Zakian; Jason A Koutcher
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

8.  A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Authors:  S Bahram Bahrami; Beryl A Hatton; Richard A Klinghoffer; Jason P Frazier; Alicia Moreno-Gonzalez; Andrew D Strand; William S Kerwin; Joseph R Casalini; Derek J Thirstrup; Sheng You; Shelli M Morris; Korashon L Watts; Mandana Veiseh; Marc O Grenley; Ilona Tretyak; Joyoti Dey; Michael Carleton; Emily Beirne; Kyle D Pedro; Sally H Ditzler; Emily J Girard; Thomas L Deckwerth; Jessica A Bertout; Karri A Meleo; Ellen H Filvaroff; Rajesh Chopra; Oliver W Press; James M Olson
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

9.  Single-shot single-voxel lactate measurements using FOCI-LASER and a multiple-quantum filter.

Authors:  Geoffrey S Payne; Nandita M deSouza; Christina Messiou; Martin O Leach
Journal:  NMR Biomed       Date:  2015-04       Impact factor: 4.044

Review 10.  ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.

Authors:  Samantha Gokhale; Ping Xie
Journal:  Pharmaceutics       Date:  2021-06-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.